These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19238935)

  • 1. [Urology].
    Jichlinski P; Wisard M
    Rev Med Suisse; 2009 Jan; 5(186):144-6. PubMed ID: 19238935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Office based urology trials.
    Casey RW; Barkin J
    Can J Urol; 2009 Aug; 16(4):4793-4. PubMed ID: 19671239
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacology for common urologic diseases: 2011 review for the primary care physician.
    Liu XS; Folia C; Gomella LG
    Can J Urol; 2011 Apr; 18 Suppl():24-38. PubMed ID: 21501548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
    Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
    Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Office based non-oncology urology trials.
    Casey RW; Barkin J
    Can J Urol; 2008 Dec; 15(6):4433-7. PubMed ID: 19046500
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms].
    Ge JP; Gong J; Ma HQ; Wei W; Shang XJ; Zhang ZY; Xu S; Wang D; Gao JP
    Zhonghua Nan Ke Xue; 2008 Oct; 14(10):927-30. PubMed ID: 19157107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The pathophysiology underlying overactive bladder syndrome possibly due to benign prostatic hyperplasia].
    Akino H; Maegawa M; Nagase K; Tanaka I; Nakai M; Ishida Y; Oyama N; Miwa Y; Yokoyama O
    Hinyokika Kiyo; 2008 Jun; 54(6):449-52. PubMed ID: 18634444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uropharmacology in primary care: 2010 update.
    Gomella LG; Lallas CD; Perkel R; Folia C; Hirsch I; Das A; Shenot P
    Can J Urol; 2010 Feb; 17 Suppl 1():35-51. PubMed ID: 20170599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Finasteride and prostate cancer].
    Ruutu M; Rannikko A
    Duodecim; 2004; 120(5):525-7. PubMed ID: 15060988
    [No Abstract]   [Full Text] [Related]  

  • 11. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
    Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
    Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in researches on the relationship between prostatic diseases and erectile dysfunction].
    Zhan JC; Wei AY
    Zhonghua Nan Ke Xue; 2005 Jun; 11(6):462-5. PubMed ID: 15999496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving effective risk-factor modification in urological patients.
    Kirby R; Kirby M
    BJU Int; 2008 Apr; 101(7):793-4. PubMed ID: 18321313
    [No Abstract]   [Full Text] [Related]  

  • 15. [Urology].
    Chollet Y; Aymon D; Cardinaux C; Praz V; Tawadros T; Treuthardt C; Vaucher L; Wisard M; Zaman K; Zarkik Y; Jichlinski P
    Rev Med Suisse; 2007 Jan; 3(94):168-71. PubMed ID: 17354544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contentious controversies: a report from the 3rd World Congress on Controversies in Urology (February 25-28, 2010, Athens, Greece).
    Rabasseda X
    Drugs Today (Barc); 2010 Apr; 46(4):291-6. PubMed ID: 20502726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A report from the 29th Annual Congress of the European Association of Urology (April 11-15 - Stockholm, Sweden).
    Rabasseda X
    Drugs Today (Barc); 2014 May; 50(5):385-95. PubMed ID: 24918838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
    Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erectile dysfunction and lower urinary tract.
    Sandner P; Neuser D; Bischoff E
    Handb Exp Pharmacol; 2009; (191):507-31. PubMed ID: 19089343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?
    da Silva CM; Cruz F
    Curr Opin Urol; 2009 Jul; 19(4):347-52. PubMed ID: 19444121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.